Literature DB >> 17068271

What is the origin of ulcerative colitis? Still more questions than answers.

Milan Lukas1, Martin Bortlik, Zdenek Maratka.   

Abstract

Despite more than a century of existence as a clinical entity, the true origin of ulcerative colitis still remains elusive. Several factors probably contribute to the development of this condition. Recently discovered technologies have clarified the role of bacterial species, which may account for intestinal dysbiosis, as a factor triggering ulcerative colitis. Genetic susceptibility together with abnormal innate immunoreactivity probably comprise the essential prerequisites for the initiation and perpetuation of ulcerative colitis. Although the genetic background has been more clearly recognised in patients with Crohn's disease than in those with ulcerative colitis, some candidate loci associated with ulcerative colitis have also been intensively studied. Additionally, environmental factors may interfere with inherent predispositions to ulcerative colitis, and either suppress or reinforce them. Whatever the origin, the search for the aetiology of ulcerative colitis must have the same goal: the improvement of treatment and the quality of life in patients with ulcerative colitis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17068271      PMCID: PMC2653902          DOI: 10.1136/pmj.2006.047035

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  48 in total

Review 1.  The neurobiology of stress and gastrointestinal disease.

Authors:  E A Mayer
Journal:  Gut       Date:  2000-12       Impact factor: 23.059

2.  Increased mucosal tumour necrosis factor alpha production in Crohn's disease can be downregulated ex vivo by probiotic bacteria.

Authors:  N Borruel; M Carol; F Casellas; M Antolín; F de Lara; E Espín; J Naval; F Guarner; J R Malagelada
Journal:  Gut       Date:  2002-11       Impact factor: 23.059

3.  [Research on the anticolon autoantibodies during hemorrhagic rectocolitis and various digestive diseases].

Authors:  Z MARATKA; V WAGNER
Journal:  Rev Fr Etud Clin Biol       Date:  1961-02

4.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology.

Authors:  Mark S Silverberg; Jack Satsangi; Tariq Ahmad; Ian D R Arnott; Charles N Bernstein; Steven R Brant; Renzo Caprilli; Jean-Frédéric Colombel; Christoph Gasche; Karel Geboes; Derek P Jewell; Amir Karban; Edward V Loftus; A Salvador Peña; Robert H Riddell; David B Sachar; Stefan Schreiber; A Hillary Steinhart; Stephan R Targan; Severine Vermeire; B F Warren
Journal:  Can J Gastroenterol       Date:  2005-09       Impact factor: 3.522

Review 5.  Is the incidence and prevalence of inflammatory bowel diseases increasing in Eastern Europe?

Authors:  L Lakatos; P L Lakatos
Journal:  Postgrad Med J       Date:  2006-05       Impact factor: 2.401

6.  Observations on the clinical course of non-specific ulcerative colitis.

Authors:  Z MARATKA; M A SPELLBERG
Journal:  Gastroenterology       Date:  1949-01       Impact factor: 22.682

7.  Preliminary observations of oral nicotine therapy for inflammatory bowel disease: an open-label phase I-II study of tolerance.

Authors:  John Robert Ingram; John Rhodes; Brian K Evans; Gareth A O Thomas
Journal:  Inflamm Bowel Dis       Date:  2005-12       Impact factor: 5.325

8.  The obligate anaerobic faecal flora of patients with Crohn's disease and their first-degree relatives.

Authors:  J P Van de Merwe; A M Schröder; F Wensinck; M P Hazenberg
Journal:  Scand J Gastroenterol       Date:  1988-11       Impact factor: 2.423

9.  The contribution of human leucocyte antigen complex genes to disease phenotype in ulcerative colitis.

Authors:  T Ahmad; A Armuzzi; M Neville; M Bunce; K-L Ling; K I Welsh; S E Marshall; D P Jewell
Journal:  Tissue Antigens       Date:  2003-12

10.  Incidence of colorectal cancer in proctocolitis: a retrospective study of 959 cases over 40 years.

Authors:  Z Maratka; J Nedbal; J Kociánová; J Havelka; J Kudrmann; J Hendl
Journal:  Gut       Date:  1985-01       Impact factor: 23.059

View more
  4 in total

Review 1.  Gastrointestinal diseases and their oro-dental manifestations: Part 2: Ulcerative colitis.

Authors:  C X W Tan; H S Brand; N K H de Boer; T Forouzanfar
Journal:  Br Dent J       Date:  2017-01-13       Impact factor: 1.626

2.  MEFV gene mutations and its impact on the clinical course in ulcerative colitis patients.

Authors:  Beytullah Yıldırım; Candan Tuncer; Derya Kan; Bilge Tunc; Mehmet Derya Demirag; E Ferda Percın; Seminur Haznedaroglu; Hakan Alagozlu
Journal:  Rheumatol Int       Date:  2010-03-12       Impact factor: 2.631

3.  Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN).

Authors:  Harald Matthes; Thomas Krummenerl; Manfred Giensch; Corinna Wolff; Jürgen Schulze
Journal:  BMC Complement Altern Med       Date:  2010-04-15       Impact factor: 3.659

4.  Experimental colitis reduces microglial cell activation in the mouse brain without affecting microglial cell numbers.

Authors:  Hoda M Sroor; Ahmed M Hassan; Geraldine Zenz; Paulina Valadez-Cosmes; Aitak Farzi; Peter Holzer; Amany El-Sharif; Fatma Al-Zahraa M Gomaa; Julia Kargl; Florian Reichmann
Journal:  Sci Rep       Date:  2019-12-27       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.